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Abstract
Complete knowledge of autoantigen spectra is crucial for understanding pathomechanisms of autoimmune diseases like
equine recurrent uveitis (ERU), a spontaneous model for human autoimmune uveitis. While several ERU autoantigens were
identified previously, no membrane protein was found so far. As there is a great overlap between glycoproteins and
membrane proteins, the aim of this study was to test whether pre-enrichment of retinal glycoproteins by ConA affinity is an
effective tool to detect autoantigen candidates among membrane proteins. In 1D Western blots, the glycoprotein
preparation allowed detection of IgG reactions to low abundant proteins in sera of ERU patients. Synaptotagmin-1, a Ca2+-
sensing protein in synaptic vesicles, was identified as autoantigen candidate from the pre-enriched glycoprotein fraction by
mass spectrometry and was validated as a highly prevalent autoantigen by enzyme-linked immunosorbent assay. Analysis
of Syt1 expression in retinas of ERU cases showed a downregulation in the majority of ERU affected retinas to 24%. Results
pointed to a dysregulation of retinal neurotransmitter release in ERU. Identification of synaptotagmin-1, the first cell
membrane associated autoantigen in this spontaneous autoimmune disease, demonstrated that examination of tissue
fractions can lead to the discovery of previously undetected novel autoantigens. Further experiments will address its role in
ERU pathology.
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Introduction
In life sciences, proteomics has become a well established and
extremely valuable research tool over the years, helpful in
exploring and understanding not only physiological processes,
but also pathogenesis of a variety of diseases on a molecular level.
Especially in the field of autoimmune diseases, researchers can
profit immensely from employing proteomic methods [1,2,3].
Equine recurrent uveitis (ERU) is an organ specific autoimmune
disease characterized by remitting-relapsing episodes of intraocu-
lar inflammation and is an established spontaneous animal model
for its human counterpart autoimmune uveitis (AU) [1]. While
causative factors and exact pathogenesis of ERU are still unknown,
proteomic methods provided helpful insights into different aspects
of the disease. Differential proteome analyses were successfully
applied through comparing target tissue or immune proteomes of
controls and ERU cases. Recently, we deciphered changed protein
expression in innate immune cells of ERU affected individuals [2].
Another important area of application is the continuous search for
autoantigens, where proteomic identification methods led to a
gradual expansion of knowledge about the ERU autoantigen
spectrum [3,4].
Binding of autoantibodies to self-antigens is an important aspect
of many autoimmune diseases, including ERU [5]. In order to
understand pathological mechanisms and use this knowledge to a
patient’s advantage, it is of paramount importance to know which
players are involved. Autoimmune attacks have grave consequenc-
es for the functionality of the targeted structure, which is, in case of
ERU, the retina. Completing our knowledge of the targeted
autoantigen spectrum, which broadens as the disease progresses
[5], would further enable us to understand heterogeneous clinical
manifestations. A challenge in this task, however, is the presence of
several sub-groups of proteins which might slip through the
reading frame of an experiment, e.g. due to low abundance in the
examined tissue. Investigating such sub-groups or fractions of
tissue proteins in detail for potential autoantigens often requires an
adaptation of the standard experimental setup in order to shift the
focal point of the experimental reading frame in the right
direction. Glycoproteins are conceivably a highly interesting
fraction of retinal proteins to explore in search for novel
autoantigen candidates, as post-translationally modified proteins
are already known to be autoantibody targets in several
autoimmune diseases [6,7] and glycosylation is the most frequent
post-translational modification [8]. Further, glycoproteins are
predominantly present on cell interfaces as membrane proteins
and are involved in a large number of cell-cell interactions [9].
Location of glycoproteins on cellular membranes makes them
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especially interesting as autoantigens, because one expects to have
a cell membrane autoantigen targeted initially in autoimmune
diseases. Breakdown of blood-retinal barrier and subsequent
infiltration of the inner eye with autoreactive immune cells is a
crucial mechanism in ERU [10,11,12]. Initiating events are
expected to take place at cell membranes as particularly exposed
barrier structures, but so far no membrane protein was identified
as autoantigen in ERU or autoimmune uveitis of man or in
experimental autoimmune uveitis models [13,14]. An impressive
example for the impact of the discovery of membrane-bound
autoantigens was the very recent identification of Aquaporin-4
(AQP4), which is the principal cellular water channel of astrocytes,
as autoantigen in neuromyelitis optica [15,16]. Its identification
was a crucial leap forward in this research field, leading to
substantial progress in understanding the pathogenesis of neuro-
myelitis optica and enabling discrimination of patients with
neuromyelitis optica from those with multiple sclerosis
[15,16,17]. This discovery of AQP4 demonstrated that ongoing
search for novel autoantigens in autoimmune diseases is not only a
matter of completing the picture, but should be continued and
intensified by all means, as its results can have profound effect on
clinical diagnosis. Interestingly, AQP4 is also linked to intraocular
inflammation, as AQP4 and Kir4.1, the two main channel
proteins in retinal Mu¨ller glia cells are differentially regulated
during ocular inflammation [18,19]. AQP4 in retinal Mu¨ller glia
cells also plays a role in ERU, where it is upregulated in uveitis
retinas, but shows a disclocation to the outer nuclear layer in its
expression pattern [20].
The aim of the study conducted here was to detect cell
membrane autoantigens in ERU, using a pre-enriched retinal
glycoprotein preparation as target. Our approach was based on
pre-enriching glycoproteins from retinal tissue via affinity to
Concanavalin A (ConA), which is a lectin widely used in
glycoprotein enrichment and isolation techniques, especially
known for its broad selectivity [21,22]. This initial enrichment
step was followed by a combination of proteomic methods,
including Western blot and mass spectrometry and the subsequent
successful validation of a candidate protein identified from the pre-
enriched glycoprotein fraction.
Materials and Methods
Retina specimen and serum samples
For this study, organic material derived from 67 healthy horses
and 134 ERU cases was examined. In the screening approach by
Western blots, sera from 17 eye-healthy horses and 17 ERU cases
were used. ELISA validation was performed with a serum cohort
of 38 eye-healthy controls and 106 ERU cases.
Retinal tissue samples from 5 healthy and 7 ERU affected eyes
were used for Western blot quantifications, retinal sections from 7
healthy and 7 ERU affected eyes were analyzed by immunohis-
tochemistry.
Eyes providing healthy porcine and healthy equine retinal
samples were obtained from animals slaughtered at a local
abattoir. ERU affected eyes derived from horses that were
diagnosed with ERU and had to be enucleated during a
therapeutical procedure. Porcine retinal samples were used for
glycoprotein enrichment. Equine retinal samples were used in
Western blot quantification and immunohistochemistry. Retina
specimens for proteomic experiments were prepared as previously
described [23]. Eyes used for healthy and ERU-affected retinal
sections in immunohistochemistry were prepared according to a
standardized protocol [24]. Eyes were considered normal based on
the diagnosis of the veterinarian present at the abattoir, medical
histories of the horses as provided by their owners, and
preliminary histological analysis. All ERU cases were patients
diagnosed with ERU at the Equine Clinic of LMU Munich,
Munich, Germany.
Ethics statement
No experimental animals were used in this study. Horses were
treated according to the ethical principals and guidelines for
scientific experiments on animals according to the ARVO
statement for the use of animals in Ophthalmic and Vision
research. Asservation of blood samples was permitted by the local
authority, Regierung von Oberbayern (Permit number: AZ 55.2-
1-54-2532.3-21-12). Blood samples were collected for purposes of
scientific research with permission from the Equine Clinic of LMU
Munich, Munich, Germany. The collection and use of equine and
porcine eyes derived from animals that were killed due to a
research-unrelated cause, was approved for purposes of scientific
research by the appropriate board of the veterinary inspection
office Munich, Germany (Permit number: 8.175.10024.1319.3).
Equine eyes were obtained with permission at Pferdemetzgerei
Veit, Deggendorf, Germany. Porcine eyes were obtained with
permission at Mu¨nchner Schlachthof Betriebs GmbH, Depart-
ment of pig slaughtering, Munich, Germany.
Enrichment of retinal glycoproteins
For retinal glycoprotein enrichment, we followed a protocol
based on a previously described method [22]. We used Conca-
navalin-A (ConA) coupled sepharose beads (ConA Sepharose 4B,
GE Healthcare, Freiburg, Germany), binding buffer (20 mM
TrisHCl, 0.5 M NaCl, 1 mM Ca2+, 1 mM Mn+, pH 7) and
elution buffer (20 mM TrisHCl, 500 mM D-mannose). Briefly,
ConA coupled sepharose beads were portioned to 500 mL and
washed four times with 1.5 ml binding buffer. Twelve healthy
retinas (derived from slaughtered pigs) were snap frozen in liquid
nitrogen and mechanically crushed. Subsequently, 500–750 mL
corresponding to 7.5 to 11 mg protein of retinal homogenate
dissolved in binding buffer were incubated with each portion of
ConA-sepharose beads, under agitation for 2 hours at 4uC. Next,
non-bound fractions were removed by washing each portion four
times with binding buffer. Afterwards, the ConA affine fraction
was eluted with 1 mL elution buffer per portion under agitation
for 2 hours at 4uC. Glycoprotein-depleted and glycoprotein-
enriched eluates were precipitated with three fold volumes of
ethanol, at 220uC over night. Precipitated proteins were collected
by centrifugation for 20 minutes, at 4uC with 100006 g and dry
pellets were stored frozen until further processing.
1D SDS Page and Western blot screening
Retinal whole lysate, glycoprotein-depleted and glycoprotein-
enriched pellets were solubilized in lysis buffer (9M urea, 2 M
thiourea, 4% CHAPS, 1% DTT), and protein content was
quantified with Bradford assay (Sigma-Aldrich, Deisenhofen,
Germany). Proteins were resolved in 1D SDS gels, then stained
with colloidal Coomassie or blotted semidry onto polyvinylidene
difluoride membranes (GE Healthcare) for Western blot experi-
ments. In Western blot screenings, unspecific binding was blocked
with 1% polyvinylpyrrolidone in PBS with 0.05% Tween20 (PBS-
T). Blots were incubated with horse serum as primary antibody
source (healthy or ERU cases, dilution 1:1000) overnight at 4uC.
After washing, blots were incubated with peroxidase-coupled
(POD) secondary antibody (goat anti horse IgG Fc-POD, dilution
1:10000; Biozol, Eching, Germany). Signals were detected by
enhanced chemiluminescence (ECL) on x-ray films (Christiansen,
Planegg, Germany).
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Mass spectrometry
LC-MS/MS mass spectrometry was performed as previously
described [25]. Briefly, the candidate protein band was excised
from the blot membrane and subjected to on-membrane tryptic
digest. Resulting peptides were separated on a reversed phase
chromatography column (PepMap, 15 cm675 mm ID, 3 mm/
100A pore size, LC Packings), which was operated on a nano-
HPLC (Ultimate 3000, Dionex, Idstein, Germany) connected to a
linear quadrupole ion-trap Orbitrap (LTQ Orbitrap XL, Thermo
Fisher Scientific, Schwerte, Germany). The mass spectrometer was
operated in the data-dependent mode to automatically switch
between Orbitrap-MS and LTQ-MS/MS acquisition. Survey full
scan MS spectra (from m/z 300 to 1500) were acquired in the
Orbitrap resolution R=60,000 at m/z 400 and up to ten most
intense ions were selected for fragmentation on the linear ion trap
using collision induced dissociation at a target value of 100,000
ions and subsequent dynamic exclusion for 30 seconds. MS/MS
spectra were used for peptide identification with Mascot (version
2.3.02, Matrix Science, London, UK; http://www.matrixscience.
com) (search parameters: carbamidomethylation set as fixed
modification, oxidation of methionines and deamidation of
asparagine and glutamine set as variable modifications, parent
ion tolerance restricted to 10 ppm and fragment ion tolerance to
0.6 Da) in the Ensembl database for pig (Sus scrofa; Sscro-
fa10.2.67.pep, downloaded from ftp://ftp.ensembl.org/pub/
current_fasta/sus_scrofa/pep/). Results were imported into Scaf-
fold (version 3.4.3; Proteome Software) and protein identification
probability threshold was set to 95%, peptide threshold to 80%
with a minimum of two peptides identified per protein.
Enzyme-linked immunosorbent assay (ELISA)
Polystyrene 96-well flat-bottomed plates (Nunc Maxisorb;
Fisher Scientific GmbH, Schwerte, Germany) were coated with
full-length recombinant synaptotagmin-1 (Acris, Herford, Ger-
many). For coating, protein was diluted at 1 mg/mL in NaHCO3
buffer (pH 9.6). Each well was incubated with 100 mL of this
dilution overnight at 4uC. To prevent nonspecific binding, plates
were blocked with 200 mL per well of 0.5% gelatin at 37uC for
1 hour. Serum samples derived from healthy horses and ERU
cases were used as primary antibody source, (dilution 1:1000, in
PBS-T), and the wells were incubated at 37uC for 1 hour (100 mL/
well) and washed with PBS-T (three times, 300 mL/well). Wells
were incubated with goat anti-horse IgG Fc POD (dilution
1:50000; Biozol, Eching, Germany) as secondary antibody
(50 mL/well for 1 hour at 37uC). Using tetramethylbenzidine
(Sigma-Aldrich) as a substrate, absorbance (OD) at 450 nm was
measured with a microplate reader after stopping the reaction with
1 M sulfuric acid (50 mL/well). Each plate contained wells in
which primary antibody incubation was omitted to enable later
correction for blank values, and in addition wells incubated with
negative control samples and positive control samples with were
determined by Western blot and confirmed in a preliminary
ELISA experiment with identical setup. The cutoff was set at a
tenfold increased SD above the average OD of negative control
samples. Absorbance values above the determined cutoff value
were counted as positive. Numbers of positive reactions in control
samples and ERU samples were compared by applying the
ChiSquare test; differences were considered significant at p#0.05.
Statistical analysis was performed with GraphPad Prism 5.04
software (Statcon, Witzenhausen, Germany). Prevalence in % was
calculated by dividing the number of positive sera by the number
of tested sera for each group.
Quantification of Syt1 expression with Western blots
Equal total protein amounts of retinal samples derived from 5
healthy controls and 7 ERU cases were loaded onto SDS Gels,
blotted, blocked and developed with ECL as already described in
section 3.2. For detection of Syt1, blots were incubated with
polyclonal rabbit anti-synaptotagmin-1 antibody (dilution 1:1000,
Abcam, Berlin, Germany) followed by goat anti rabbit IgG POD
(dilution 1:3000, Sigma-Aldrich). Western blots signals were
imaged on a transmission scanner using LabScan 5.0 software
and quantified by densitometry with ImageQuantTL software (all
GE Healthcare). Signals were normalized to beta-actin content
after staining of lanes with monoclonal mouse anti beta-actin
antibody (dilution 1:5000, Sigma-Aldrich) prior to statistical
analysis. As Kolmogorov-Smirnov test showed that data were
not distributed normally (p#0.05), Mann-Whitney test was
applied for calculation of statistical significance (p#0.05). Statis-
tical analysis was performed using Paleontological Statistics
software (PAST, http://folk.uio.no/ohammer/past/index.html).
Immunohistochemistry
Posterior eyecups were fixed in Bouin’s solution (Sigma-Aldrich)
as previously described [20]. The resulting tissue blocks [24] were
sectioned to 8 mm and mounted on coated slides (Superfrost,
Menzel, Braunschweig, Germany). Heat antigen retrieval was
performed at 99uC for 15 minutes in 0.1 M EDTA-NaOH buffer
(pH 8.0). To prevent nonspecific antibody binding, sections were
blocked with 1% bovine serum albumin (BSA) in Tris-buffered
saline containing 0.05% Tween20 (TBS-T) and 5% goat serum for
40 minutes at RT for 3 h at room temperature. Using polyclonal
rabbit anti-synaptotagmin-1 (dilution 1:1500; Abcam) and mono-
clonal mouse anti Glucose-regulated protein 78 (GRP78) antibody
(dilution 1:50, BD Biosciences, Heidelberg, Germany), primary
antibody incubation was performed over night. Sections were
incubated with appropriate Alexa Fluor-labeled secondary IgG
antibodies for 30 minutes at room temperature. For anti-
synaptotagmin-1, goat anti-rabbit IgG alexa647 was used, for
anti GRP78, we used goat anti-mouse IgG coupled to alexa546
(dilution 1:500; all from Invitrogen, Karlsruhe, Germany). All
antibodies were diluted in TBS-T containing 1% BSA. Cell nuclei
were counterstained with DAPI (dilution of 1:1000; Invitrogen). As
last step, sections were mounted with glass coverslips using
fluorescent mounting medium. Fluorescent images were recorded
with Axio Imager M1 or Z1 (Zeiss, Go¨ttingen, Germany) and the
Axio Vision 4.6 software (Zeiss).
Results
Retinal glycoproteins enriched by ConA affinity are
suitable for 1D Western blot screening
Retinal glycoproteins were pre-enriched by taking advantage of
lectin affinity, following a protocol based on a method previously
described by Naim and Koblet [22]. Briefly, ConA-coupled
sepharose beads were incubated with retinal tissue. While the non-
glycoprotein retinal fraction, which did not bind to ConA was
removed, glycoproteins bound to the beads due to their affinity to
ConA and were retrieved by elution with D-mannose. For control
of enrichment efficacy, we stained protein patterns of unfraction-
ated retinal tissue, retinal glycoprotein-depleted fraction and
glycoprotein-enriched fractions after separation with SDS gels.
Gels were stained with colloidal Coomassie blue and compared
based on differential staining patterns and intensities (Figure 1, A–
C). While staining patterns of unfractionated retinal tissue (Fig. 1A)
and glycoprotein-depleted fraction (Fig. 1B) were quite similar, the
glycoprotein-enriched fraction (Fig. 1C) clearly differed from these
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two. This indicated that the bulk of high abundant, non-
glycosylated proteins was left behind in the unbound fraction
and we had successfully enriched glycoproteins from retinal tissue.
Since many protein bands that were stained in the glycoprotein
fraction (Fig. 1C), were not visible in retinal whole lysate (Fig. 1A)
although equal amounts of total protein were loaded, we conclude
that many of these proteins would not have been detected without
enrichment due to their low abundance. Also, although the
fraction of enriched proteins consisted of low abundant proteins,
the great variety of bands in this fraction (Fig. 1C) demonstrated
that we achieved better access to not only a few, but a fairly large
number of potential autoantigens which were previously unde-
tectable. Retinal glycoprotein preparation was then tested for IgG
specific autoimmune reactions in 1D Western Blots. Sera from
healthy controls and ERU cases were tested for autoreactive
immune responses to the glycoprotein fraction (Fig. 1D healthy,
Fig. 1E ERU). A protein band of a MW slightly less than 70 kDa,
which was not bound by any control samples, was clearly bound
by ERU IgG (Fig. 1E). Subsequently, this protein band was clearly
identified with mass spectrometry as synaptotagmin-1 (Table 1).
Synaptotagmin-1 (abbrev. Syt1) is a N-glycosylated protein with a
crucial role in the Ca2+-triggered exocytosis of synaptic vesicles
[26,27], reflecting the N-type glycoprotein affinity of ConA, the
lectin used in the pre-enrichment step. Gene ontology annotations
for the cellular location of this protein included synaptic vesicle
membrane and plasma membrane (source: UniProt Database,
Accession number P21579). As Syt1 was never identified as ERU
autoantigen candidate in previous studies, this experiment
demonstrated that the enrichment efficacy of the applied method
was sufficient to enable a detection of serum IgG reactions specific
for this protein fraction.
Prevalence of serum IgG specific for SYT1 significantly
higher in ERU group
In order to verify our finding from the proteomics experiment
and validate our novel glycoprotein autoantigen Syt-1, we
performed an indirect Enzyme-linked immunosorbent assay
(ELISA) to detect anti Syt1 autoantibodies using purified Syt1 as
a target. This experiment provided us with two important results
(Figs. 2A and 2B): first, Syt1 was specifically targeted by
autoreactive IgGs (Fig. 2A) and second, the prevalence of Syt1
autoantibodies in the ERU group was 56% (Fig. 2B). Comparing
the prevalence of Syt1 specific autoantibodies between ERU cases
(Fig. 2A, right, black dots) and healthy controls (Fig. 2B, left, white
dots), we found a significantly higher occurrence of Syt1
autoantibodies in ERU group (p#0.05). ELISA results illustrating
the reaction behavior of all individual serum samples are presented
in Figure 2.
Reduced Syt1 expression in ERU affected retinas
Each protein has specific functions and is part of a biological
network. Determining its expression levels in health and disease
can provide information about whether dysregulations occur in
diseased state, which in turn leads to a more detailed assessment of
a protein’s role in disease and a better understanding of
pathogenesis-related mechanisms. Quantification by Western blot
revealed that Syt1 expression was significantly (p#0.05) reduced in
ERU retinas (Fig. 3, right, black bar) to 24% (SD 634%) of signal
intensity in healthy retinal tissues (Fig. 3, left, white bar). Only in
one ERU cases tested, Syt1 did not decrease, indicating that there
are ERU affected individuals where retinal Syt1 expression is
unchanged, recovers or decreases at varying points in the course of
disease. However, the majority of ERU cases had significantly less
Syt1 expression in retina. This indicates, that Syt1 is not stably
expressed in retinal tissue unlike the already known ERU
autoantigens, cellular retinaldehyde-binding protein, S-antigen
and interphotoreceptor retinoid-binding protein [28]. Since Syt1
expression sites in equine retina were not described to date, we
performed immunohistochemistry to localize Syt1 in horse retina
(Fig. 4). In normal equine retina (Fig. 4A), Syt1-signaling was most
Figure 1. Retinal glycoprotein preparation in 1D SDS-Gel,
stained with colloidal Coomassie and in 1D Western blot. (MW):
Molecular weight marker, (A) retinal whole-tissue lysate, untreated, (B)
retinal glycoprotein-depleted fraction after lectin affinity chromatogra-
phy, (C) retinal glycoprotein fraction enriched by lectin affinity. Similar
staining patterns of lanes A and B as opposed to different band pattern
in lane C indicate a successful enrichment of normally low-abundant
glycoproteins. (D) Representative 1D Western blots of glycoprotein-
enriched retinal fractions, incubated with healthy control serum
showing no reaction to retinal glycoproteins, (E) and incubated with
serum of an ERU case that reacted to candidate protein band (arrow).
doi:10.1371/journal.pone.0050929.g001
Table 1. Candidate glycoprotein band as identified by Liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/
MS).
Protein nameA Accession numberB Gene nameC Peptide countD
Synaptotagmin-1 ENSSSCP00000001015 SYT1 3
(A): Protein name: Name of the identified protein.
(B)Accession number as listed in Ensembl database (http://www.ensembl.org),
(C)Gene name as listed in HGNC database (http://www.genenames.org/),
(D)Number of peptides the protein was identified with. Syt1 was identified with an identification probability of 100%.
doi:10.1371/journal.pone.0050929.t001
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prominent in retinal ganglion cells, followed by cells of the inner
nuclear layer with additional staining occurring in nerve fiber
layer, inner and outer plexiform layer and photoreceptor outer
segments (Fig. 4D). The signal in retinal ganglion cells and cells of
the inner nuclear layer was located in cell somata (Fig. 4D, Syt1
expression: red color). Aforementioned additional Syt1 expression
foci in other layers were less clearly demarcated and of lower signal
intensity (Fig. 4D). This staining pattern most likely reflects the
meshwork structure in these layers, which are mostly composed of
synapses and cellular processes reaching out from the adjacent
layers containing the associated cell somata [24]. Due to the low
extent of staining observed here, we hypothesize that in normal
equine retina only a subset of synapses in the plexiform layers
contains Syt1. Double-staining of retinal sections with antibodies
to Syt1 and Glucose-related protein 78 (GRP78), a previously
described marker for ganglion cells in the equine retina [29],
confirmed expression of Syt1 in retinal ganglion cells by complete
signal colocalization with Syt1 for this cell type in healthy samples
(Fig. 4E, overlay of staining: yellow color). In addition to retinal
ganglion cells, GRP78 stained a population of cells in the inner
nuclear layer [29]. Interestingly, we observed a co-localization of
GRP78 and Syt1 in most cells of the inner nuclear layer, although
single-positive cells for both GRP78 and Syt1 occurred occasion-
ally (Fig. 4G). Significant changes in Syt1 expression occurred in
uveitic retinas (Fig. 4B) compared to healthy state. In ERU
affected retinas, our most frequent observation was an overall
reduction of Syt1 (Fig. 4F, representative ERU case), consistent
with our findings from Western blot quantification (Fig. 3). Most
structures showed a clear decrease of SYT1 staining in ERU, while
remnant staining was observed primarily in retinal ganglion cells
(Fig. 4F, representative ERU case). In plexiform layers, we
observed an overall reduction of Syt1 signal. The number of Syt1-
positive cells in the inner nuclear layer was generally decreased as
well. Double-staining of GRP78 and Syt1 in ERU retinas
confirmed an unchanged abundance of retinal ganglion cells in
ERU, demonstrated by equal expression of GRP78 in both states
(Fig. 4C and D, GRP 78 expression green). Contrary to this, we
observed a clear decrease of Syt1 signal intensity in retinal
ganglion cells and a decrease in Syt1 positive cells in the inner
nuclear layer (Fig. 4F). Overlay of both signals in ERU specimen
(Fig. 4H) confirmed that reduction of Syt1 expression in ERU
affected retinas was not caused by complete destruction of Syt1-
Figure 2. Prevalence of anti Syt1 sera IgG autoantibodies detected by indirect ELISA. Figure 2A: Anti-synaptotagmin-1 positive IgG in
healthy sera (left, white dots) and ERU cases (right, black dots). Each dot represents the absorbance value of an individual serum sample, measured at
450 nm). The Cut-off value was set at the mean value of negative controls plus the 10-fold standard deviation, represented by the horizontal
separation line. In ERU samples, anti-Syt1-autoantibodies are more frequently present than in healthy samples (* = p#0.05). Figure 2B: Comparison of
positive reactions (black) and negative reactions (white) in control sera (left bar) and ERU samples (right bar) expressed in per cent. While in controls,
the prevalence of positive IgG reactions to Syt1 was 37%, prevalence in the ERU group was 56%. Prevalence in percent was calculated by dividing
numbers of positive samples by numbers of tested samples in each group.
doi:10.1371/journal.pone.0050929.g002
Figure 3. Unequal Syt1 expression in healthy and ERU affected
retinal tissues. Western blot quantification of Syt1 expression in
healthy retinas (white bar, n = 5) and ERU (black bar, n = 7). Represen-
tative Syt-1 blots for each group are inserted above respective bars (left,
healthy and right, ERU). The band at 68 kDa was used for quantification
(arrows). Mean signal intensity of control samples was set as a 100%,
mean signal intensity in ERU samples was significantly reduced to 24%
(634%) (* = p#0.05).
doi:10.1371/journal.pone.0050929.g003
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containing structures, since unchanged GRP78 expression dem-
onstrated that respective structures were still present in ERU.
Discussion
There is still a need to identify novel autoantigens in
autoimmune diseases, because the emergence of novel autoanti-
body targets does not only complete our knowledge about the
pathomechanisms of disease, but has also profound consequences
for diagnosis and therapeutic approach to autoimmune diseases.
This was recently shown for the autoantigen APQ4 in neuromy-
elitis optica, because detection of this cell membrane expressed
antigen enabled stratification of patients with neuromyelitis optica
from those with multiple sclerosis. This led to a new understanding
of the factors behind clinical symptoms in this disease and
subsequently paved the way for novel therapeutic strategies, which
included blocking of the pathogenic binding of IgG to AQP4 and
prevented its detrimental downstream effects [15,16,30]. The
astrocytic water channel AQP4 is an integral membrane protein
[15] and thus belongs to the subgroup of membrane proteins,
where one would expect to find a large number of proteins
targeted in autoimmune diseases, as these proteins are often found
on cell boundaries which would be easily accessible for autoreac-
tive immune cells and antibodies. In ERU, a spontaneous model
for human autoimmune uveitis, a highly effective workflow for
identification and validation of autoantigens was established in the
past [5], however, no membrane protein was identified as
autoantigen to date. It became clear that while unfractionated
retinal tissue was an excellent antigenic source in previous
screening experiments [3,4], answering more specific questions
required a specific adaptation of the experimental reading frame.
In this study, prefractionation of retinal tissue as autoantigenic
source for Western blot screenings was tested as a potential
solution for this problem and proved to be an elementary step in
order to specifically examine protein subgroups for potential novel
autoantigens. In this case, glycoproteins, which, as previously
mentioned, are predominantly found on cell membranes [9] were
the focus point of examination. Results of our study clearly
demonstrated, that enriching retinal glycoproteins via ConA
affinity successfully reduced the complexity of retinal tissue as
antigen pool in 1D Western blot screenings and enhanced the
detectability of serum IgG reactions to low abundant glycoproteins
(Fig. 1). This enabled us to identify and validate Syt1, a N-
glycosylated transmembrane protein [31] and the first identified
membrane protein target for ERU autoantibodies. While lectin
affinity is widely taken to enrich glycoproteins for quantitative
proteome analysis or differential proteomics [32,33], the value of
this fractionation method for the detection of novel autoantigens in
autoimmune diseases was not fully exploited yet and might
therefore lead to new and exciting insights. This is underlined by
the fact that in the search for ERU autoantigens, we conducted
successful studies in the past, which followed a basic proteomic
workflow of identification and validation similar to the one applied
in this study, but were based on the whole retinal proteome as
autoantigenic source, without a preliminary enrichment step, and
Syt1 never appeared as candidate in these studies [3,5]. Syt1 is a
protein integral to synaptic vesicle membranes, where it acts as
sensor for the increase of cytoplasmatic Ca2+ that occurs after an
opening of Ca2+ channels in response to an incoming action
potential. Though the full details of this process are not yet
understood, by interaction with the SNARE-complex, the binding
of Ca2+ to Syt1 initiates the fusion of the vesicle membrane with
the cell membrane, which is required for exocytosis of neuro-
transmitters into the synaptic cleft [26,27,34,35,36,37]. Recent
evidence suggested that Syt1 additionally has a positive regulatory
effect on axonal branching during neuronal development [38].
Members of the synaptotagmin family were reported to be
differentially expressed in a variety of neurodegenerative afflic-
tions, including Parkinson’s disease and Alzheimer’s disease [39].
In patients affected with Alzheimer’s disease, a downregulation of
Syt1 was observed in different brain regions [39]. A dysregulation
of hippocampal Syt1 expression was also reported in patients with
mesial temporal lobe epilepsy, where it decreased and in the
refractory group of patients of temporal lobe epilepsy, where it
increased [39].
As autoantibody target, Syt1 was previously described in
Lambert-Eaton myasthenic syndrome, an immune-mediated
paraneoplastic disease affecting neuromuscular junctions, where
it was suggested that Syt1 specific autoantibodies might interfere
with presynaptic mechanisms and thus impair neuromuscular
function [40,41,42,43,44,45]. It is very likely that in ERU affected
retina, the binding of autoreactive IgG to Syt1 also hinders
previously mentioned physiological functions of Syt1 in neuro-
transmitter release, leading to a general dysregulation of functional
circuits in the transmission of visual stimuli. According to our
results in immunohistochemical analysis, this would affect a variety
of cell types, including retinal ganglion cells, photoreceptors and a
cell population in the inner nuclear layer. Via immunohistochem-
istry, the downregulation of Syt1 that we detected in ERU state
was demonstrated to be independent of apparent destruction of
physiological expression sites, thus we hypothesize that an active
downregulation is the driving factor behind the reduction of Syt1
content in ERU affected retina specimens. Interestingly, down-
regulation of Syt1 in ERU as described in this study confirmed
findings from a previous study analyzing differential protein
expression of retinal membrane proteins. This result was not
further verfied at that time, but already showed that Syt1 was
downregulated in ERU retina [25]. Possible reasons for a Syt1
downregulation might be a reduced expression due to cellular
stress during autoimmune attacks, a lacking ability to regenerate
physiological levels of Syt1 that was destroyed or rendered
ineffective by autoantibody binding or a consequence of dysreg-
ulated upstream factors influencing Syt1 expression which were
not detected yet. While these hypotheses do not exclude each other
and might even occur concurrently, the last mentioned possibility
is probably the one that is most compelling to explore in future
studies, as e.g. the synaptic vesicle protein SV2B, which interacts
with Syt1, did not only influence expression levels of Syt1, but also
of several other synaptic vesicle proteins in retinal tissue [46]. In
addition, our findings in immunohistochemistry were especially
Figure 4. Immunohistochemical analysis of Syt1 expression changes in ERU retina. Left panels: representative healthy retina; right panels:
representative ERU case. Differential interference contrast images of healthy (A) and ERU affected (B) retinal specimen demonstrating that in ERU
state, normal retinal architecture is disturbed. GRP78 (green color), a marker staining retinal ganglion cells and a population of inner nuclear layer
cells in equine retina was equally expressed in physiological (C) and ERU state (D). Synaptotagmin-1 (Syt1, red color) signal in healthy retina (E) was
most prominent in retinal ganglion cell somata, their axons in the nerve fiber layer and in somata of a cell population in the inner nuclear layer, with
additional staining foci in the outer and inner plexiform layer and photoreceptor outer segments, while ERU affected retinal sections (F), presented
with a clearly reduced overall Syt1 signal. Overlay of GRP78 and Syt1 signals (G: healthy, H: ERU) indicated that in the ERU affected section, Syt1
expression is reduced, although structures expressing it in physiological state are still present. Cell nuclei were counterstained with DAPI (blue color).
doi:10.1371/journal.pone.0050929.g004
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interesting, as they corroborated previous evidence pointing to
species specific differences of retinal Syt1 expression, setting
equine retina apart from mouse retina, where in immunohisto-
chemistry, Syt1 was observed mostly in the plexiform layers
[46,47]. Koontz and Hendrickson described a somatic Syt1 signal
in primate retina and attributed it to somata and fibers of
displaced amacrine cells for the ganglion cell layer, and in the
inner nuclear layer to bipolar cell axons and somata and amacrine
cell somata [48]. However, due to the previously mentioned
colocalization of Syt1 with GRP78 and the signal in the nerve fiber
layer, evidence points to retinal ganglion cells as main site of Syt1
expression in the equine retinal ganglion cell layer. As Syt1 was
shown to be part of the photoreceptor outer segment proteome
[49,50], we conclude that the signal we observed in photoreceptor
outer segments is specific. Interestingly, Synaptotagmin-1 is also
expressed in other neuronal tissues apart from the retina, for
example in pinealocytes [51]. Other antigens in ERU [52] are also
known to be expressed in retina and pineal gland, for example S-
Antigen [53,54] and IRBP [55]. In ERU patients, a concurrent
pinealitis is known to develop [56], and as it is expressed in both
retina and pineal gland, Synaptotagmin-1 as autoantigen might
contribute to pineal immunopathology in ERU. As Synaptotag-
min-1 is an autoantigen which is not exclusively expressed in
retina, another interesting question that will be approached in
future studies is whether there are any local intraocular factors that
cause an autoimmune response against this antigen which is
detrimental locally, but not systemically. Autoimmunity against
systemic antigens that led to organ-specific symptoms only was
already described in a mouse model of rheumatoid arthritis [57].
After immunization with the ubiquitous protein Glucose-6-
Phosphate Isomerase, genetically unaltered mice developed joint-
specific symptoms [57]. Reasons for this mechanisms are still
unclear, but it was proposed that locally increased concentration of
G6PI in joints might contribute to the initiation of the immune
response against this protein and that local, joint-specific factors
like regulation of cytokine expression might lead to development of
a pathogenic response [57]. In order to validate the identification
of Syt1 as autoantigen and to assess the prevalence of anti Syt1
IgG serum reactions, indirect ELISA was performed. We were
able to validate our identification from Western blot screening and
observed that serum IgG indeed target Syt1, and that they have a
prevalence of 56% in the ERU group (Fig. 2B), with significantly
more positive reactions in the ERU group (* = p#0.05) compared
to healthy control sera. While reactions occurred in both groups,
IgG autoantibodies to Syt1 in the healthy and ERU group might
differ in their properties, for example their affinity or the epitope
that is bound. Another important factor to consider is that equine
IgG comprise seven subclasses [58]. A difference in subclass of Syt-
1 targeting autoantibodies might be decisive in harmless versus
harmful autoreactivity, as it is known that IgG can recruit pro-
inflammatory or anti-inflammatory pathways, depending on their
subclass or post-translational modifications [59,60], as it was
observed for example in rheumatoid arthritis, where a changed
glycosylation pattern of IgG is associated with pathogenesis [61].
For equine IgG, only limited information about their functions is
available. It is already known that IgG1, IgG3, IgG4, IgG5 and
IgG7 are probably able to interact with Fc receptors on immune
effector cells and that IgG1, IgG3, IgG4 and IgG7 are able to bind
complement C1q [58]. Thus, functional differences might also be
of interest for ERU research, as they might explain why
autoreactivites against a specific protein are harmless in some
animals, but associated with ERU in others. Thus, future studies
should ideally aim at a thorough comparison of IgG properties in
ERU affected individuals versus healthy individuals. The question
whether the seven equine IgG subclasses have a role in
determining whether an individual is susceptible to ERU or
whether they influence the course of disease needs to be answered
in the future. Unfortunately, a lack of specific tools is currently
preventing studies of this aspect, as currently available reagents are
specific for the obsolete classification IgGa, IgGb, IgGc and IgGT,
and are not able to provide a valid distinction between all seven
IgG isotypes of the horse [58].
In addition, autoreactive sera IgG specific for certain targets are
proven biomarkers in some autoimmune diseases [15] and were
shown to possess important predictive value in several diseases, for
example type I diabetes [62]. In a large scale studies with children,
a specific constellation of IgG autoantibodies indicated develop-
ment of type I diabetes later in life, these predictive autoantibodies
were present for several years before diabetes developed [62].
ERU has a high prevalence of 10% [63] and it is possible that sera
tested in our ELISA were accidentally derived from individuals
that were healthy at the time of sampling, but are at risk of
developing ERU in the future. One of the most important
questions that will have to be answered in future studies is whether
Synapotagmin-1 as autoantigen is directly pathogenic in ERU.
This could be answered e.g. by testing its ability to induce
experimental uveitis in horses via immunization with this protein.
Having learned from our results that Syt1 is a significant factor in
ERU, further studies will be necessary in order to assess the
physiological role of Syt1 in equine retina and its precise role in
ERU pathology.
Conclusions
Results of this study will have several implications for future
projects. First, we demonstrated that a pre-fractionation of
autoantigenic targets is an effective preliminary step to reduce
sample complexity and to enrich for interesting protein subgroups.
Glycoprotein isolation by ConA affinity proved a suitable method
to search for membrane-bound autoantigens. Further adaptations
of these experimental settings might enable the examination of
other retinal protein fractions, for example the O-glycosylated
fraction instead of the N-glycosylated fraction that was enriched by
using Con-A affinity, and lead to the discovery of even more novel
autoantigens The identification of Syt1 as novel membrane
autoantigen with a high autoantibody prevalence in the ERU
group strongly suggests that an impairment of neurotransmitter
release plays a role in ERU and its reduced expression in ERU
affected retina indicates an active downregulation. Interestingly,
Syt1 might not be de-regulated in all ERU cases, pointing to a
need for further investigation of factors that might be associated
with Syt1 downregulation and anti Syt1 autoantibodies.
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